Kamada Ltd. | Balance Sheet

Fiscal year is January-December. All values ILS Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
257,468.40
201,950.70
110,140.10
110,194.50
149,346.90
189,049.70
Total Accounts Receivable
70,836.20
72,863.50
97,575.90
83,877.50
110,995.60
111,713.90
Inventories
76,129.40
98,932.30
102,474.70
98,502.30
73,147.70
109,546.60
Other Current Assets
4,054.10
4,471.30
3,404.70
4,068.00
2,853.70
4,058.10
Total Current Assets
408,488.10
378,217.80
313,595.30
296,642.40
336,343.90
414,368.20
Net Property, Plant & Equipment
74,428.70
84,713.00
82,914.40
85,628.60
87,409.20
93,433.70
Total Investments and Advances
-
295.80
136.20
153.90
-
-
Long-Term Note Receivable
79.80
-
-
-
-
-
Intangible Assets
492.90
400.80
210.10
1,270.10
-
459.60
Other Assets
295.00
-
-
-
170.10
190.60
Total Assets
483,784.50
463,627.40
396,856.00
383,695.00
423,923.20
516,105
ST Debt & Current Portion LT Debt
30,260.20
29,847.40
626.50
1,785.80
2,135.10
Accounts Payable
48,916.80
63,633.00
65,342.40
62,444.30
62,611.20
Other Current Liabilities
33,901.30
27,100.10
23,287.90
40,476.30
37,309.80
Total Current Liabilities
113,078.20
120,580.50
89,256.80
104,706.40
102,056.10
Long-Term Debt
33,724.20
4,463.50
587.50
5,249.60
4,756.20
Provision for Risks & Charges
2,870.50
2,809.60
3,062.30
2,778.70
3,971.60
Other Liabilities
29,524.30
27,298.50
21,821.00
14,089.90
2,454.50
Total Liabilities
179,197.30
155,152.10
114,727.60
126,824.60
113,238.30
Common Equity (Total)
304,587.20
308,475.20
282,128.40
256,870.40
310,684.90
Total Shareholders' Equity
304,587.20
308,475.20
282,128.40
256,870.40
310,684.90
Total Equity
304,587.20
308,475.20
282,128.40
256,870.40
310,684.90
Liabilities & Shareholders' Equity
483,784.50
463,627.40
396,856.00
383,695.00
423,923.20

About Kamada

View Profile
Address
Science Park
Rehovot TA 7670402
Israel
Employees -
Website http://www.kamada.com
Updated 07/08/2019
Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through the following business segments: Proprietary Products, and Distribution. The Proprietary Products segment develops, manufactures and sells plasma-derived protein therapeutics products.